scPharmaceuticals (NASDAQ:SCPH) Receives “Buy” Rating from HC Wainwright

scPharmaceuticals (NASDAQ:SCPHGet Rating)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Tuesday, TipRanks reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 195.86% from the company’s current price.

Separately, SVB Leerink reissued a “hold” rating and issued a $5.00 price target on shares of scPharmaceuticals in a report on Friday, January 21st.

NASDAQ SCPH traded down $0.11 during trading hours on Tuesday, reaching $5.07. The stock had a trading volume of 838 shares, compared to its average volume of 31,379. The company’s fifty day moving average is $5.34. The stock has a market cap of $138.77 million, a PE ratio of -4.92 and a beta of 0.36. scPharmaceuticals has a 52-week low of $3.48 and a 52-week high of $7.66. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.13.

scPharmaceuticals (NASDAQ:SCPHGet Rating) last issued its earnings results on Tuesday, March 22nd. The company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.07. On average, equities analysts forecast that scPharmaceuticals will post -1.52 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Morgan Stanley increased its position in shares of scPharmaceuticals by 44.6% during the first quarter. Morgan Stanley now owns 54,289 shares of the company’s stock worth $361,000 after purchasing an additional 16,748 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of scPharmaceuticals during the second quarter worth approximately $353,000. Advisor Group Holdings Inc. increased its position in shares of scPharmaceuticals by 980.4% during the third quarter. Advisor Group Holdings Inc. now owns 3,857 shares of the company’s stock worth $25,000 after purchasing an additional 3,500 shares in the last quarter. AIGH Capital Management LLC increased its position in shares of scPharmaceuticals by 92.2% during the third quarter. AIGH Capital Management LLC now owns 1,234,121 shares of the company’s stock worth $8,207,000 after purchasing an additional 591,967 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of scPharmaceuticals by 7.1% during the third quarter. Geode Capital Management LLC now owns 71,223 shares of the company’s stock worth $473,000 after purchasing an additional 4,748 shares in the last quarter. 59.44% of the stock is owned by institutional investors and hedge funds.

scPharmaceuticals Company Profile (Get Rating)

scPharmaceuticals, Inc engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Featured Articles

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.